

Gallium-PSMA and other tracers for prostate cancer: Do they really help?

Poster Session 45

Sunday, 13 March
14:00 - 15:30

Location: Room 14c (ICM, Level 1)

Chairs: F. Abdollah, West Bloomfield (US)
G. Ploussard, Toulouse (FR)
T. Wiegel, Ulm (DE)

Aims and objectives of this presentation

Gallium-PSMA PET is suggested to be an emerging tool in staging of prostate cancer. Conflicting data, however, have been published concerning its use for lymph node staging or diagnosis of prostate cancer relapse. This session will highlight the most recent data on new PET tracers for prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

14:23 - 14:33

Is seeing more enough to do more?

T. Wiegel, Ulm (DE)

557

Localization of primary prostate cancer by simultaneous ⁶⁸Gallium-HBED-CC-PSMA PET and multiparametric MRI

By: Eiber M.¹, Weirich G.², Nguyen N.³, Holzapfel K.⁴, Souvatzoglou M.¹, Haller B.⁵, Rauscher I.¹, Beer A.⁶, Wester H.-J.⁷, Westenfelder K.³, Gschwend J.³, Schwaiger M.¹, Maurer T.³

Institutes:¹Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ²Technical University of Munich, Dept. of Pathology, Munich, Germany, ³Technical University of Munich, Dept. of Urology, Munich, Germany, ⁴Technical University of Munich, Dept. of Radiology, Munich, Germany, ⁵Technical University of Munich, Dept. of Medical Statistics and Epidemiology, Munich, Germany, ⁶University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany, ⁷Technical University of Munich, Dept. of Pharmaceutical Radiopharmacy, Munich, Germany

*558

Diagnostic efficacy of ⁶⁸Ga-PSMA PET for lymph node staging and metastatic distribution in patients with intermediate to high-risk prostate cancer

By: Maurer T.¹, Gschwend J.¹, Pähr L.¹, Rauscher I.², Souvatzoglou M.², Haller B.³, Weirich G.⁴, Wester H.-J.⁵, Heck M.¹, Hacker C.¹, Kübler H.¹, Beer A.⁶, Schwaiger M.², Eiber M.²

Institutes:¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ³Technical University of Munich, Institute for Medical Statistics and Epidemiology, Munich, Germany, ⁴Technical University of Munich, Institute of Pathology, Munich, Germany, ⁵Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, ⁶University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany

*559

Prospective evaluation of ⁶⁸Ga-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer

By: Van Leeuwen P.¹, Emmett L.², Ho B.², Delprado W.³, Stricker P.¹

Institutes:¹St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²St. Vincent's Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, ³University of Notre Dame, Dept. of Histopathology, Sydney, Australia

*560

⁶⁸Ga-PSMA PET/CT provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer

By: Herlemann A.¹, Wenter V.², Kretschmer A.¹, Bartenstein P.², Stief C.¹, Gratzke C.¹, Fendler W.²

Institutes:¹Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ²Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany

*561

Evaluation of detection rate of 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy

By: Paffen M.L.J.E.¹, Murphy D.², Costello A.², Hicks R.³, Hoffman M.³

Institutes:¹Royal Melbourne Hospital, Dept. of Urology, Wodonga, Australia, ²Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ³Peter MacCallum Cancer Centre, Dept. of Nuclear Medicine, Melbourne, Australia

*562

Accuracy of 18f-facbc (anti1-amino-3-18f-fluorocyclobutane-1-carboxylic acid) in prostate cancer relapse: Results of a prospective trial

By: Pultrone C.V.¹, Bianchi L.¹, Brunocilla E.¹, Fanti S.², Nanni C.², Zanoni L.², Matti A.², Borghesi M.³, Bravi C.¹, Martorana G.¹, Schiavina R.¹

Institutes:¹St Orsola Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, ²St Orsola Hospital, University of Bologna, Dept. of Nuclear Medicine, Bologna, Italy, ³St Orsola Hospital, University of Bologna, Dept. of Urology and Medical and Surgical Sciences, Bologna, Italy

*563

The diagnostic accuracy of 68Ga-PSMA-PET/CT for detection of lymph node metastases in the setting of salvage lymph node dissection

By: Jilg C.A.¹, Drendel V.², Beck T.³, Rischke C.³, Grosu A.⁴, Werner M.², Wetterauer U.¹, Meyer P.³, Schultze-Seemann W.¹

Institutes:¹University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany, ³University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, ⁴University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

*564

The role of 68Ga-PSMA PET/CT in the diagnosis and therapeutic decision making of oligometastatic recurrence after radical prostatectomy

By: Tosco L.¹, Gheysens O.², Deroose C.², De Meerleer G.³, Haustermans K.⁴, Everaerts W.¹, Cromphout L.¹, Van Poppel H.¹, Van Laere K.², Joniau S.¹, Goffin K.²

Institutes:¹UZ Leuven, Dept. of Development and Regeneration, Leuven, Belgium, ²UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ³University Hospitals Ghent, Dept. of Radiotherapy, Ghent, Belgium, ⁴UZ Leuven, Dept. of Radiotherapy, Leuven, Belgium

*565

Probability of positive PET imaging with a [68Ga]-labelled PSMA ligand based on PSA value in patients with biochemical recurrent prostate cancer after radical prostatectomy

By: Cromphout L.¹, Tosco L.¹, Everaerts W.¹, Albersen M.¹, Gheysens O.², Deroose C.², Van Laere K.², Goffin K.², Joniau S.¹

Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium

*566

68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients

By: Eiber M.¹, Pyka T.¹, Okamoto S.¹, Rauscher I.¹, Dahlbender M.², Tauber R.², Retz M.², Gschwend J.², Schwaiger M.¹, Maurer T.²

Institutes:¹Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ²Technical University of Munich, Dept. of Urology, Munich, Germany

*567

PET imaging of therapy-naïve primary prostate cancer patients using the GRPr-targeting ligand Sarabesin 3

By: Bakker I.L.¹, Fröberg A.C.¹, Busstra M.B.², Van Leenders G.J.L.H.³, De Blois E.¹, Schoots I.⁴, Veenland J.⁴, Maina T.⁵, Van Weerden W.M.², Nock B.A.⁵, De Jong M.¹

Institutes:¹Erasmus MC, Dept. of Nuclear Medicine, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ⁵NCSR "Demokritos", Dept. of Radiochemistry, Athens, Greece

*568

PSMA pet improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: Implications for selection and assessment for active surveillance and focal therapy

By: Rhee H.¹, Thomas P.², Shepherd B.³, Greenslade S.⁴, Vela L.¹, Russell P.⁵, Nelson C.⁵, Chung E.⁶, Wood G.⁷, Malone G.⁸, Wood S.⁸, Heathcote P.⁸

Institutes:¹Princess Alexandra Hospital/ Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ²Royal Brisbane and Women's Hospital, Dept. of Nuclear Medicine, Brisbane, Australia, ³Princess Alexandra Hospital, Dept. of Anatomical Pathology, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Dept. of Radiology, Woolloongabba, Australia, ⁵Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Dept. of Urology, Woolloongabba, Australia, ⁷Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia, ⁸Princess Alexandra Hospital/Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia